Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy of hepatitis C]

D M Alscher1, J C Bode

  • 1Zentrum für Innere Medizin, Robert-Bosch-Krankenhaus, Stuttgart.

Medizinische Klinik (Munich, Germany : 1983)
|March 15, 1997
PubMed
Summary

Interferon-alpha therapy for hepatitis C, especially chronic cases, offers a 20% long-term benefit with a 12-month treatment plan. Factors like HCV genotype influence treatment success, but combination therapies require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction of dispersed cubic phases with blood components.

International journal of pharmaceutics·2013
Same author

Pacemaker infection with propionibacterium and a nephritic sediment.

Clinical nephrology·2008
Same author

New facts about encapsulating peritoneal sclerosis as a sequel of long-term peritoneal dialysis - what can we do?

Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2007
Same author

[Disturbances in volume and electrolytes with intestinal and kidney diseases].

Der Internist·2006
Same author

Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease.

Journal of clinical pathology·2006
Same author

Urinary excretion of polyethylene glycol 3350 during colonoscopy preparation.

Zeitschrift fur Gastroenterologie·2006

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Context:

  • Hepatitis C virus (HCV) infection poses a significant global health challenge.
  • Current therapeutic strategies primarily focus on Interferon-alpha based treatments.
  • Understanding treatment efficacy and influencing factors is crucial for patient management.

Purpose:

  • To provide an updated review of Interferon-alpha therapy for hepatitis C.
  • To establish evidence-based guidelines for practical therapeutic use.
  • To discuss emerging therapeutic strategies and unresolved clinical questions.

Summary:

  • Acute hepatitis C treatment with Interferon-alpha (3 million units thrice weekly for 3-4 months) improves viral elimination.
  • Chronic hepatitis C management recommends a standard Interferon-alpha monotherapy (5-6 million units thrice weekly for 12-16 weeks, then 3 million units thrice weekly for 12 months).
  • A sustained response rate of approximately 20% is achievable, influenced by factors such as HCV genotype, viral load, disease duration, hepatic iron, and cirrhosis.

Impact:

  • Defines established guidelines for Interferon-alpha therapy in hepatitis C.
  • Highlights prognostic factors influencing treatment outcomes.
  • Identifies areas needing further research, including combination therapies and management of non-responders or flare-ups.

Related Experiment Videos